克唑替尼治疗28例间变性淋巴瘤激酶阳性晚期非小细胞肺癌疗效分析  

Efficacy of crizotinib for 28 cases of advanced ALK-positive non-small cell lung cancer

作　　者：王文娴[1] 宋正波[1] 余新民[1] 娄广媛[1] 古翠萍[1] 施勋[1] 赵珺[1] 张沂平[1] 

机构地区：[1]浙江省肿瘤医院胸部肿瘤内科浙江省胸部肿瘤重点实验室,杭州310022

出　　处：《中华肿瘤杂志》2015年第10期784-787,共4页Chinese Journal of Oncology

基　　金：浙江省中医药科研基金项目（2015ZB020）;浙江省自然科学基金（LYl3H160024）;卫生部医药卫生科技发展研究中心课题（W2012FZ134）

摘　　要：目的：探讨克唑替尼治疗间变性淋巴瘤激酶（ ALK）阳性晚期非小细胞肺癌（ NSCLC）的疗效和安全性。方法28例ALK阳性晚期NSCLC患者口服克唑替尼胶囊，分析克唑替尼的临床疗效和不良反应。结果28例患者的客观有效率和疾病控制率分别为71．4％（20／28）和92．9％（26／28），3例患者完全缓解，17例患者部分缓解。患者的不良反应以视觉影响和消化道反应为主，发生视觉闪烁11例，恶心呕吐9例，腹泻8例，均为Ⅰ度；仅1例患者出现了Ⅲ度骨髓抑制。28例患者中，疾病无进展16例；疾病进展12例，中位无进展生存时间为8．2个月。结论 ALK阳性晚期NSCLC患者接受克唑替尼治疗具有较好的近期疗效且不良反应多可耐受。Objective This study aims to evaluate the efficacy and safety of crizotinib for advanced ALK？positive non？small cell lung cancer （ NSCLC） patients. Methods Twenty？eight patients with advanced ALK？positive NSCLC were given orally crizotinib 250 mg b. i. d., and were followed up to evaluate the therapeutic efficacy and safety. Results Among the 28 patients, the objective response rate （ ORR） was 71.4%（20/28） and disease control rate （DCR） was 92.9% （26/28）. Three patients achieved complete response. Seventeen patients had partial response. The most common drug？related adverse events were mild flickering vision and gastrointestinal reaction. Eleven patients experienced flickering vision. Nine patients had nausea and vomiting. Eight patients had diarrhea. They were all reversible and of grade Ⅰ or Ⅱ. Only one patient had grade Ⅲ myelosuppression. Among the 28 patients, 16 cases were disease？free and 12 cases had progressive disease, with a progression？free survival of 8.2 months. Conclusions Crizotinib is effective and tolerable in the treatment of advanced ALK？positive NSLCC. However, its long？term treatment efficacy requires to be further studied.

关 键 词：癌 非小细胞肺 治疗结果 间变性淋巴瘤激酶 克唑替尼 

分 类 号：R734.2[医药卫生—肿瘤]